The season of common cold viruses has started. Due to a phenomenon called "interference", this COULD actually be helping a bit against SARS-CoV-2.
But interference is short-lived, so it is neither an argument to drop the mask mandates, nor to refrain from getting vaccinated
1/10
So what is interference? It means that infection by one virus can be inhibitory to other viruses (either same or different species) that come a bit afterwards. This can be observed both in cell culture and in epidemiology
2/10
The molecular mechanisms behind it can be different, but the most important factor is (drum roll....)
Interferon (IFN) are cytokines, i.e. small messenger molecules (protein, not RNA) that are produced and secreted by infected cells. IFNs alarm other cells and prompt them to go into a so-called antiviral state. On short term and at the local level this is great...
4/10
...but if the entire organism is involved because infection has spread already widely - that's not healthy at all, it is actually part of the "cytokine storm" that is causing severe COVID-19
5/10
So if cells are in an antiviral state, they are much better at fending off virus infections.
This can explain why people rarely have the flu and a cold (typically by rhinoviruses) at the same time:
6/10 thelancet.com/journals/lanmi…
Similarly to flu, rhinoviruses can protect to some extent from infection by SARS-CoV-2:
7/10 rupress.org/jem/article/21…
But again: this is not a perfect or long-term protection, but a transient phenomenon. The only long-term protection is the vaccine, and a mask helps you to keep SARS-CoV-2 out while actually not protecting that well from rhinoviruses
8/10 nature.com/articles/s4159…
So with the mask, you may have a double benefit by filtering out SARS-CoV-2 AND still catching the extra short-term protection by common cold rhinoviruses.
And please...
9/10
don't rip your mask off and take a deep breath when someone next to you is sneezing. You can't know it s really rhinoviruses, could be something much more nasty.
10/10
• • •
Missing some Tweet in this thread? You can try to
force a refresh
...ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections ≥21 d after the first dose (61% ...versus 66%)..., after a second dose...(79% versus 80%)...respectively
...largest reductions...for symptomatic...and/or infections with a higher viral burden 1/5
Overall,...largest benefit...after two vaccinations and against symptomatic and high viral burden infections, and with no evidence of a difference between the BNT162b2 and ChAdOx1 vaccines. 2/5
...benefits associated with vaccination were much greater for infection...with...high levels of viral shedding...estimated at 91%...post-second dose
...75%...effectiveness following one dose ≥21 d ago...
3/5
- of people who tested positive for the virus
(-> includes people who never got severe symptoms):
13.7% still reported symptoms after at least 12 weeks
-> "...more than one in 10...who became infected with SARS-CoV-2 have gone on to get long COVID"
2/17
Age distribution:
"prevalence was 25.6% at 5 weeks for those between 35 and 49 years old...less common in younger...and older..."
"children can get long COVID...Yet some medical professionals play down the idea, says Sammie Mcfarland" (UK support group Long Covid Kids)
3/17
Und wenn wir gerade dabei sind: Auch hier ist noch überhaupt nicht geklärt, ab das jetzt schlimm ist oder nicht. Meines Erachtens fehlen da noch einige Kontrollen, um das Ergebnis wirklich einschätzen zu können.
1/13
Was haben die Forscher gefunden? In 3 verschiedenen Chargen des AZ-Impfstoffs wurden ordentliche Mengen an humanen Proteinen nachgewiesen, darunter auch Hitzeschockproteine (HSPs)
2/13
HSPs sind eine tolle Sache, sie bewahren unsere Proteine in den Zellen davor, sich falsch zu falten und dadurch evt toxisch zu werden. Solche Fehlfaltungen gibt es gesteigert, wenn die Temperatur ansteigt, daher der Name.
3/13
Interesting article about incomplete immune protection after virus infection. Bottom line: getting herd immunity by herd infection is impossible as only people with severe systemic disease get profound immunity. Vacination does not have this problem 1/8 journals.plos.org/plospathogens/…
"It is often messaged that herd immunity to...SARS-CoV2 ...will protect nonvaccinated individuals...
However, seasonal CoVs...remain endemic...
If immunity to SARS-CoV-2 and seasonal CoVs are similar, COVID-19 herd immunity is a pipe dream" 2/8
"Absent effective herd immunity, over the next few years, individuals can choose whether their first exposure to SARS-CoV-2 immunogens occurs via vaccination or infection..." 3/8
Hier noch etwas Vertiefung zu dieser Publikation über Impfschema und Fluchtmutationen. Was ist die beste Strategie bei limitierten Mengen an Impfstoff: möglichst viele Menschen 1 mal impfen (Bsp UK),...1/10 nature.com/articles/s4157…
...oder besser den Impflingen pünktlich beide Dosen verabreichen (Bsp D)?
Cobey et al plädieren für Ersteres, also eine maximale Abdeckung mit einer Impfdosis. Variante dieser „dose-sparing“ Strategie: 2 mal impfen, aber mit der Hälfte der empfohlenen Dosis. 2/10
Sorge dabei ist ja, dass die „Halb“-Geimpften nur eine Teilimmunität haben, und das Virus sich deshalb noch genug vermehren kann, um Immun-Escape („Flucht“)-Mutationen auszubilden. 3/10
Eine gute (wenn auch erwartbare) Nachricht: schon die erste mRNA-Impfung baut nach ca 12 Tagen einen solchen Schutz auf, dass man eine reduzierte Viruslast hat. Es ist zu erwarten, dass das zu einer leichteren Symptomatik und niedrigeren Infektiosität führt. Dazu passt... 1/5
...dass Affen, die aufgrund einer Infektion oder durch Behandlung mit Antikörpern eine gewisse Immunität haben, nach (erneuter) Infektion keine aktive Virusvermehrung in der Nase haben...2/5 jvi.asm.org/content/95/8/e…
...und ja schon zuvor gezeigt wurde, dass 21 Tage nach der ersten mRNA-Impfung ein 70%iger Schutz vor Infektion besteht 3/5 papers.ssrn.com/sol3/papers.cf…